TASCENSO ODT® (fingolimod) Archives

Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of TASCENSO ODT^® (fingolimod)

Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce its intention to commercialize TASCENSO ODT® (fingolimod) in the US multiple sclerosis (MS) market in Q1 2023.
Eligible patients will receive full MS patient support program through Cycle Vita™

Tag: TASCENSO ODT® (fingolimod)

Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of TASCENSO ODT^® (fingolimod)

Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023